Senior Director, Global Market Access

Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing.

Cogent Biosciences is seeking an entrepreneurial and strategic Senior Director, Global Market Access to develop and execute market access strategies that enable patients with cancer to access innovative therapies.

Reporting to the Vice President, Value & Access Strategy, this role will have a global remit with some responsibility for the US market. The Sr. Director will work across the organization to translate clinical and economic value into compelling market access strategies across key markets.

The role will partner closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Finance, and other cross-functional teams, while working closely with the company's HEOR capabilities within the Value & Access organization to develop evidence and value strategies that support payer and HTA decision-making.

The ideal candidate brings strong oncology market access experience, a solid understanding of payer and reimbursement dynamics, and experience developing access strategies across international markets. This is a highly visible, hands‑on role in a growing biotech environment, requiring both strategic thinking and the ability to drive execution with lean internal resources and external partners.

Global Market Access & Value Strategy

• Develop and execute global market access strategies for oncology pipeline and commercial products across the product lifecycle.
• Identify market access opportunities, risks, and potential barriers across the US and priority international markets.
• Develop market‑specific strategies informed by payer dynamics, reimbursement and HTA requirements, clinical practice, treatment pathways, and competitive landscapes.
• Integrate market access, pricing, reimbursement, HEOR, and value considerations into broader product, development, and commercialization strategies.
• Monitor changes in oncology treatment, reimbursement, and health‑system environments and assess implications for the portfolio.

Evidence, HEOR & Oncology Value Strategy

• Lead the integration of market access and HEOR perspectives into the overall value strategy for oncology assets.
• Translate the clinical profile, unmet need, and treatment landscape into differentiated payer and HTA value propositions.
• Partner closely with HEOR and Medical Affairs to define evidence requirements and develop evidence‑generation strategies across key markets.
• Provide market access input into clinical development plans, endpoints, comparators, patient populations, and evidence‑generation priorities.
• Identify evidence gaps that may create future access barriers and work with HEOR and cross‑functional teams to address them.
• Guide development of value dossiers, economic models, budget impact analyses, and other market access tools in partnership with HEOR.
• Ensure HEOR outputs are effectively translated into payer, HTA, and broader market access strategies.

Pricing & Reimbursement

• Develop…